These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1007 related articles for article (PubMed ID: 28782469)

  • 1. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation: checkpoint blockade etc.
    Curry WT; Lim M
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii26-vii31. PubMed ID: 26516223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.
    Lucchesi M; Sardi I; Puppo G; Chella A; Favre C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1047-1053. PubMed ID: 29067473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
    Francis DM; Thomas SN
    Adv Drug Deliv Rev; 2017 May; 114():33-42. PubMed ID: 28455187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Pignata S; Banna GL
    Crit Rev Oncol Hematol; 2019 Jul; 139():87-90. PubMed ID: 31112887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Development of Immune Checkpoint Inhibitors.
    Wang J; Yang T; Xu J
    Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
    Chen TT
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
    Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
    Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibitors in immunotherapy of ovarian cancer.
    Wang DH; Guo L; Wu XH
    Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.